Inhibitors of Akt activity
    4.
    发明授权
    Inhibitors of Akt activity 失效
    Akt活性抑制剂

    公开(公告)号:US07399764B2

    公开(公告)日:2008-07-15

    申请号:US10530252

    申请日:2003-10-24

    摘要: The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

    摘要翻译: 本发明涉及含有与被抑制Akt(丝氨酸/苏氨酸蛋白激酶)活性的取代吡嗪部分稠合的五元杂环的化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法,包括施用本发明化合物。

    Somatostatin Agonists
    9.
    发明申请
    Somatostatin Agonists 审中-公开
    生长抑素激动剂

    公开(公告)号:US20090258853A1

    公开(公告)日:2009-10-15

    申请号:US12225027

    申请日:2007-03-09

    摘要: This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.

    摘要翻译: 本发明涉及作为生长抑素的激动剂并且对生长抑素受体亚型SSTR2有选择性的化合物。 该化合物可用于治疗和预防糖尿病以及糖尿病相关病理学,包括视网膜病变,神经病变和肾病。 许多化合物是口服活性的。 因此,本发明的目的是描述这些化合物。 进一步的目的是描述生长抑素激动剂的具体优选的立体异构体。 另一个目的是描述制备这些化合物的方法。 另一个目的是描述使用这些化合物作为其活性成分的方法和组合物。